Bioequivalence study of commercial imidazole dipeptides in healthy adults.

Bioequivalence study of commercial imidazole dipeptides in healthy adults. - Bioequivalence study of commercial imidazole dipeptides in healthy adults.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000023079

Enrollment

Registered

2016-07-08

Start date

2016-06-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Commercial imidazole dipeptide A, washout, Commercial imidazole dipeptide B Commercial imidazole dipeptide B, washout, Commercial imidazole dipeptide A

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Healthy males and females aged 20 to less than 60 years old. 2) Subjects who can make self-judgment and are voluntarily giving written informed consent.

Exclusion criteria

Exclusion criteria: 1) Subjects who have systolic blood pressure over 150 mmHg. 2) Subjects who have total serum cholesterol over 260 mg/dL. 3) Subjects who have ALT, AST and ganma-GTP more than twice the standard value.

Design outcomes

Primary

Measure	Time frame
Cmax AUCt	—

Secondary

Measure	Time frame
Cmax AUCt	—

Countries

Japan

Contacts

Public ContactKenichiro Sato

Tokaibussan Co., Ltd Sales department

sato@tokaibsn.co.jp03-3864-6861

Outcome results